These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 29573215

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
    Barnett AH, Arnoldini S, Hunt B, Subramanian G, Hoxer CS.
    Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
    [Abstract] [Full Text] [Related]

  • 5. Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.
    Lage MJ, Fabunmi R, Boye KS, Misurski DA.
    Adv Ther; 2009 Feb; 26(2):217-29. PubMed ID: 19219409
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
    Nauck MA, McGuire DK, Pieper KS, Lokhnygina Y, Strandberg TE, Riefflin A, Delibasi T, Peterson ED, White HD, Scott R, Holman RR.
    Cardiovasc Diabetol; 2019 Sep 03; 18(1):116. PubMed ID: 31481069
    [Abstract] [Full Text] [Related]

  • 8. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
    Rascati KL, Worley K, Meah Y, Everhart D.
    J Manag Care Spec Pharm; 2017 Mar 03; 23(3):299-306. PubMed ID: 28230454
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost efficiency of canagliflozin versus sitagliptin for type 2 diabetes mellitus.
    Ektare VU, Lopez JM, Martin SC, Patel DA, Rupnow MF, Botteman MF.
    Am J Manag Care; 2014 Oct 03; 20(10 Suppl):S204-15. PubMed ID: 25495002
    [Abstract] [Full Text] [Related]

  • 16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Oct 03; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 17. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
    Guillermin AL, Lloyd A, Best JH, DeYoung MB, Samyshkin Y, Gaebler JA.
    J Med Econ; 2012 Oct 03; 15(4):654-63. PubMed ID: 22369345
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Resource use and costs of type 2 diabetes in Sweden - estimates from population-based register data.
    Ringborg A, Martinell M, Stålhammar J, Yin DD, Lindgren P.
    Int J Clin Pract; 2008 May 03; 62(5):708-16. PubMed ID: 18355236
    [Abstract] [Full Text] [Related]

  • 20. Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.
    Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, Riefflin A, Tankova T, Wainstein J, Peterson ED, Holman RR, TECOS Study Group.
    Diabetes Obes Metab; 2017 Nov 03; 19(11):1587-1593. PubMed ID: 28432745
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.